Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On May 11, 2022, Avenue Therapeutics, Inc. (the "Company") appointed David Jin as the Company's Interim Principal Financial Officer. Mr. Jin is also serving as the Company's Interim Principal Executive Officer and Chief Operating Officer.

Mr. Jin, 32, also serves as Vice President of Corporate Development at Fortress Biotech ("Fortress"). Prior to Fortress, he was a member of the Private Equity group at Barings focused on control equity and asset-based investments in pharma and biotech. Before that, he was Director of Corporate Development at Sorrento Therapeutics, Inc. (Nasdaq: SRNE) and Vice President of Healthcare Investment Banking at FBR & Co. He began his career in management consulting at IMS Health (now IQVIA). Mr. Jin has a Bachelor of Science degree in Industrial Engineering & Management Sciences with a double-major in Mathematical Methods in the Social Sciences from Northwestern University.

No family relationships exist between Mr. Jin and any of the Company's directors or executive officers. There are no arrangements between Mr. Jin and any other person pursuant to which Mr. Jin was selected as the Company's Interim Principal Financial Officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Jin has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

© Edgar Online, source Glimpses